The agreement involves Allergan, Janssen, Teva, CVS, Walgreens, and Walmart, who collectively face allegations of misrepresenting opioid safety and ignoring suspicious prescription volumes. While the companies deny any wrongdoing, the settlement fund is designated to compensate private health plans, managed Medicaid programs, and ERISA-governed entities that shouldered the financial burden of addiction treatment and opioid distribution over the last three decades.
In section Releases
Third-Party Payors Secure $180 Million Opioid Settlement
A $180 million class action settlement has been reached with major pharmaceutical manufacturers and pharmacy chains, resolving claims that they fueled the opioid crisis through deceptive marketing and failed distribution oversight. Eligible third-party payors now have until December 1, 2026, to file claims for costs incurred from 1996 through June 2026.
Claimants must navigate specific filing requirements to secure a portion of the funds, which will also cover administrative costs and legal fees. Those wishing to retain their right to pursue independent litigation against the defendants must formally exclude themselves by August 13, 2026. A final fairness hearing is scheduled for September 23, 2026, where the court will evaluate the proposed distribution, including requests for attorney compensation capped at 20 percent of the total settlement.
Comments (0)
No comments yet. Be the first!